Wegovy Injection Sites: What the Label Specifies

Where a subcutaneous medication goes is spelled out in its FDA label, and Wegovy is no exception — so the reliable answers come straight from the prescribing information. Explore the full Peptides & GLP-1 library.

Wegovy is administered as a subcutaneous injection, and the approved product label sets out the acceptable sites, rotation practice, and what to avoid. What follows reports those points from the prescribing information and describes what your provider walks through when therapy begins. It is reference context, not a substitute for that hands-on training.

Where the label allows injection

Per the FDA-approved prescribing information, Wegovy is injected subcutaneously into the abdomen, thigh, or upper arm. Each dose must go into the subcutaneous tissue — the fat layer just beneath the skin — and never into muscle or a vein. When used correctly with the supplied instructions-for-use booklet, the pen delivers the dose at a fixed depth.

Rotating sites the right way

The label directs rotating injection sites within an anatomical area — for example, moving to a different spot within the abdomen from one dose to the next — to reduce localized skin reactions. Skin that is broken, tender, red, bruised, scarred, or hardened should be avoided, and the same exact spot should not be used on consecutive doses.

What the label rules out

Wegovy is for subcutaneous use only.

Practices to avoid

Do not inject into muscle, into a vein, or through clothing, and never into an IV access line. Pens should not be shared because of cross-contamination risk, and the medication should not be mixed with another injectable in the same syringe unless a provider specifically directs it. If a pen looks damaged, the solution is cloudy or discolored, or it has been exposed to extreme temperature, it should not be used.

Injection-site reactions to watch

Mild redness, itching, or a small raised area at the site is common and usually resolves within hours to a day. Contact a provider for redness or warmth that persists or spreads, a lump that does not resolve, bleeding that will not stop, or signs of infection such as fever, worsening tenderness, or pus. Any allergic-reaction symptom — widespread rash, facial or throat swelling, or difficulty breathing — warrants urgent or emergency care.

Training that comes with a protocol

Specific technique beyond the label belongs to a prescribing provider’s training, and PlexusDx Weight Management Protocols — including Semaglutide Injection and Tirzepatide Injection — include provider consultation covering pen handling, storage, and recognizing reactions. Underneath the mechanics sits biology: variants in GLP1R and FTO shape baseline GLP-1 and appetite. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights for context and never predicts response to any medication.

Storage and pen handling basics

Beyond where the needle goes, the label sets expectations for the pen itself. A pen that looks damaged, holds a solution that appears cloudy or discolored, or has been exposed to extreme temperature should not be used, and pens are never shared between people because of cross-contamination risk. Proper storage protects the medication between doses, and a prescribing provider covers those specifics — along with disposal of used pens and needles — when therapy begins. These handling details are part of the same provider training that covers technique, which is why a general article points to that consultation rather than trying to substitute for it.

The reason the label is this specific is that consistency protects both the medication and the person using it. A pen kept and handled correctly delivers the dose as designed, while a mishandled one introduces variables no article can account for. When a question comes up about a particular pen, a stored dose, or a site that looks irritated, the prescribing provider — not a search result — is the right place to take it, because they know your history and your specific protocol.

Frequently Asked Questions

Where does the label say to inject Wegovy?

The FDA-approved prescribing information lists the abdomen, thigh, and upper arm as acceptable subcutaneous sites. Injections go into the fat layer just under the skin, never into muscle or a vein. Rotate within an area each week and avoid broken, tender, bruised, scarred, or hardened skin.

Can I reuse the same spot each week?

No. The label directs rotating sites within an anatomical area to reduce localized skin reactions, so the same exact spot should not be used on consecutive doses. Moving around within the abdomen or alternating between the thigh and abdomen is acceptable. Ask your provider for specific rotation guidance.

What should I do about an injection-site reaction?

Mild redness, itching, or a small bump usually settles within a day. Contact your provider for spreading redness or warmth, a persistent lump, bleeding that will not stop, or infection signs like fever and pus. Widespread rash, swelling of the face or throat, or trouble breathing needs emergency care.

Does the site I choose change how well it works?

All three label sites — abdomen, thigh, and upper arm — are acceptable. Absorption varies modestly between sites in pharmacology studies, but consistent weekly dosing and proper rotation matter far more to real-world outcomes than site choice. Follow your provider’s guidance for your specific situation.

Continue learning inside the PlexusDx Education Hub. Browse more Peptides & GLP-1 education.